{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:45:20Z","timestamp":1793835920364,"version":"4.6.1"},"reference-count":141,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hospital-level Disciplines-Chronic Disease Group-Cervical Diagnosis and Treatment Centre and Obstetrics Endocrinology","award":["YJXK-2021-11"],"award-info":[{"award-number":["YJXK-2021-11"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Human papillomavirus (HPV) persistent infection is a major pathogenic factor for HPV-related cancers, such as cervical cancer (CC), vaginal cancer, vulvar cancer, anal cancer, penile cancer, and head and neck cancer (HNC). Since the introduction of the world\u2019s first prophylactic HPV vaccine, there has been a decline in the incidence of HPV infections and associated cancers. This article reviews the latest literature on the research progress, efficacy, and safety of HPV vaccines for these cancers, providing a reference for HPV vaccination strategy. Methods: By utilizing databases such as PubMed, Google Scholar, CNKI, and Wanfang, we conducted a literature search on research papers related to HPV vaccines from 2014 to 2024, employing keywords such as \u201cHPV\u201d, \u201cHPV vaccine\u201d, \u201cCC\u201d, \u201dvaginal cancer\u201d, \u201cvulvar cancer\u201d, \u201canal cancer\u201d, \u201cpenile cancer\u201d and \u201cHNC\u201d. Additionally, we reviewed the latest information available on official websites, including the World Health Organization (WHO). Based on the quality and relevance of the papers, we selected over 100 of the most representative articles for further summarization and analysis. Results: Vaccination against HPV can effectively block the transmission of the virus and prevent HPV-related cancers. Current studies have confirmed the efficacy and safety of prophylactic HPV vaccination. However, numerous challenges remain. The global vaccination rate for preventive vaccines remains low, particularly in low- and middle-income countries. Nonetheless, in the future, we can enhance the accessibility, affordability, and coverage of HPV vaccines by expanding the indications of already licensed vaccines, continuously developing new vaccines. Conclusions: The HPV vaccine is an extremely effective measure for the prevention and treatment of HPV-related cancers. Although there are many challenges in expanding the coverage of the HPV vaccine. It is believed that in the not-too-distant future, both prophylactic and therapeutic HPV vaccines will achieve commendable results.<\/jats:p>","DOI":"10.3390\/vaccines12111291","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T04:53:05Z","timestamp":1731991985000},"page":"1291","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Human Papillomavirus-Related Cancer Vaccine Strategies"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2971-6689","authenticated-orcid":false,"given":"Xia","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Gynaecology, Minhang Hospital, Fudan University, Shanghai 201199, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, Minhang Hospital, Fudan University, Shanghai 201199, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"ref_1","first-page":"794","article-title":"Condylomata acuminata and human genital cancer","volume":"36","author":"Hausen","year":"1976","journal-title":"Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-67452-6_1","article-title":"Human papillomavirus-associated cancers","volume":"1313","author":"Alhamlan","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e28950","DOI":"10.1002\/jmv.28950","article-title":"Advances in HPV-associated tumor management: Therapeutic strategies and emerging Insights","volume":"95","author":"Gong","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_5","unstructured":"World Health Organization(WHO) (2024, November 05). Immune Coverage. Available online: https:\/\/www.who.int\/zh\/news-room\/fact-sheets\/detail\/immunization-coverage."},{"key":"ref_6","unstructured":"World Health Organization(WHO) (2024, September 05). HPV Vaccine Included in National Immunization Programme. Available online: https:\/\/app.powerbi.com\/view?r=eyJrIjoiNDIxZTFkZGUtMDQ1Ny00MDZkLThiZDktYWFlYTdkOGU2NDcwIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yousefi, Z., Aria, H., Ghaedrahmati, F., Bakhtiari, T., Azizi, M., Bastan, R., Hosseini, R., and Eskandari, N. (2021). An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.805695"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Contreras, A., S\u00e1nchez, S.A., Rodr\u00edguez-Medina, C., and Botero, J.E. (2024). The role and impact of viruses on cancer development. Periodontology 2000.","DOI":"10.1111\/prd.12566"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-virology-092818-015716","article-title":"Hitchhiking of viral genomes on cellular chromosomes","volume":"6","author":"Coursey","year":"2019","journal-title":"Annu. Rev. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bpobgyn.2020.02.009","article-title":"HPV vaccination and cancer Prevention","volume":"65","author":"Athanasiou","year":"2020","journal-title":"Best. Pr. Res. Clin. Obs. Gynaecol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Biryukov, J., Myers, J.C., McLaughlin-Drubin, M.E., Griffin, H.M., Milici, J., Doorbar, J., and Meyers, C. (2017). Mutations in HPV18 E1^E4 impact virus capsid assembly, infectivity competence, and maturation. Viruses, 9.","DOI":"10.3390\/v9120385"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1158\/1541-7786.MCR-20-0491","article-title":"Cellular functions of HPV16 E5 oncoprotein during oncogenic transformation","volume":"19","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e01582-19","DOI":"10.1128\/JVI.01582-19","article-title":"Human papillomavirus 16 E5 inhibits interferon signaling and supports episomal viral maintenance","volume":"94","author":"Scott","year":"2020","journal-title":"J. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103675","DOI":"10.1016\/j.critrevonc.2022.103675","article-title":"Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies","volume":"174","author":"Bhattacharjee","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Har\u0119\u017ca, D.A., Wilczy\u0144ski, J.R., and Paradowska, E. (2022). Human papillomaviruses as infectious agents in gynecological cancers. Oncogenic properties of viral proteins. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031818"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101224","DOI":"10.1016\/j.mam.2023.101224","article-title":"Vaccines for HPV-associated diseases","volume":"94","author":"Skolnik","year":"2023","journal-title":"Mol. Asp. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Jensen, J.E., Becker, G.L., Jackson, J.B., and Rysavy, M.B. (2024). Human papillomavirus and associated cancers: A review. Viruses, 16.","DOI":"10.3390\/v16050680"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chen, Z., DeSalle, R., Schiffman, M., Herrero, R., Wood, C.E., Ruiz, J.C., Clifford, G.M., Chan, P.K.S., and Burk, R.D. (2018). Niche adaptation and viral transmission of human papillomaviruses from archaic hominins to modern Humans. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007352"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hao, L., Jiang, Y., Zhang, C., and Han, P. (2024). Genome Composition-based deep learning predicts oncogenic potential of HPVs. Front. Cell Infect. Microbiol., 14.","DOI":"10.3389\/fcimb.2024.1430424"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Warburton, A., Redmond, C.J., Dooley, K.E., Fu, H., Gillison, M.L., Akagi, K., Symer, D.E., Aladjem, M.I., and McBride, A.A. (2018). HPV integration hijacks and multimerizes a cellular enhancer to generate a viral-cellular super-enhancer that drives high viral oncogene expression. PLoS Genet., 14.","DOI":"10.1371\/journal.pgen.1007179"},{"key":"ref_21","first-page":"65","article-title":"Human papilloma virus: A review study of epidemiology, carcinogenesis, diagnostic methods, and treatment of all HPV-related cancers","volume":"35","author":"Soheili","year":"2021","journal-title":"Med. J. Islam. Repub. Iran."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e1568809","DOI":"10.1080\/2162402X.2019.1568809","article-title":"Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape","volume":"8","author":"Dharmaraj","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"107750","DOI":"10.1016\/j.celrep.2020.107750","article-title":"TBC1D5-catalyzed cycling of Rab7 is required for retromer-mediated human papillomavirus trafficking during virus entry","volume":"31","author":"Xie","year":"2020","journal-title":"Cell Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1002\/mco2.368","article-title":"Human papillomavirus associated cervical lesion: Pathogenesis and therapeutic interventions","volume":"4","author":"Ye","year":"2023","journal-title":"MedComm"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bpobgyn.2017.08.015","article-title":"The natural history of human papillomavirus Infection","volume":"47","author":"Brotons","year":"2018","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/vim.2019.0020","article-title":"HPV18 E1 Protein Plus \u03b1-Galactosylceramide Elicit in Mice CD8+ T Cell Cross-Reactivity Against Cells Expressing E1 from Diverse Human Papillomavirus Types","volume":"32","author":"Arciniega","year":"2019","journal-title":"Viral Immunol."},{"key":"ref_27","first-page":"827","article-title":"Interpretation of Chinese expert consensus on the clinical application of human papillomavirus vaccine (2021 version)","volume":"38","author":"Li","year":"2022","journal-title":"J. Pract. Obstet. Gynecol."},{"key":"ref_28","first-page":"126","article-title":"HPV infection-related disease burden and comprehensive prevention and control measures","volume":"33","author":"Li","year":"2022","journal-title":"Chin. J. Matern. Child. Health Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e2537","DOI":"10.1002\/rmv.2537","article-title":"Human papillomavirus infection: Epidemiology, biology, host interactions, cancer development, prevention, and Therapeutics","volume":"34","author":"Wolf","year":"2024","journal-title":"Rev. Med. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e1345","DOI":"10.1016\/S2214-109X(23)00305-4","article-title":"Global and Regional Estimates of Genital Human Papillomavirus Prevalence among Men: A Systematic Review and Meta-Analysis","volume":"11","author":"Bruni","year":"2023","journal-title":"Lancet Glob. Health"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Borena, W., Kitchen, M., Gisinger, M., Taylor, N., Oberkofler, H., Dewasurendra, D., Widschwendter, A., Stoiber, H., von Laer, D., and Sarcletti, M. (2024). Disproportionate preponderance of HPV genotypes associated with anogenital warts among HIV-positive MSM. Front. Public Health, 12.","DOI":"10.3389\/fpubh.2024.1437309"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMcp2108502","article-title":"Human papillomavirus vaccination","volume":"388","author":"Markowitz","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_33","unstructured":"GlaxoSmithKline(GSK) (2024, October 06). GSK Data on File. Available online: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/."},{"key":"ref_34","first-page":"1543","article-title":"Prevalence of Human Papillomavirus subtypes 16 and 18 among Yemeni Patients with Cervical Cancer","volume":"18","author":"Ahmed","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_35","first-page":"101","article-title":"Update on safety and efficacy of HPV vaccines: Focus on Gardasil","volume":"10","author":"Soliman","year":"2021","journal-title":"Int. J. Mol. Cell Med."},{"key":"ref_36","first-page":"18","article-title":"Research progress and vaccination strategy of human papillomavirus vaccine","volume":"40","author":"Su","year":"2024","journal-title":"Chin. J. Pract. Gynecol. Obstet."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wang, R., Huang, H., Yu, C., Li, X., Wang, Y., and Xie, L. (2024). Current status and future directions for the development of human papillomavirus vaccines. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1362770"},{"key":"ref_38","unstructured":"GSK (2024, November 05). China Approves Cervarix Two-Dose Vaccine Schedule for Girls Aged 9 to 14 Against Certain Types of Cancer-Causing human Papillomavirus. Available online: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/china-approves-cervarix-two-dose-vaccine-schedule-for-girls-aged-9-to-14-against-certain-types-of-cancer-causing-human-papillomavirus\/."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"102467","DOI":"10.1016\/j.ctrv.2022.102467","article-title":"HPV vaccination and HPV-related malignancies: Impact, strategies and optimizations toward global immunization coverage","volume":"111","author":"Giannone","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s40265-014-0255-z","article-title":"Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil\u00ae): A review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital Warts","volume":"74","author":"McCormack","year":"2014","journal-title":"Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1017\/S0950268817000747","article-title":"Human papillomavirus 9-valent vaccine for cancer prevention: A systematic review of the available evidence","volume":"145","author":"Signorelli","year":"2017","journal-title":"Epidemiol. Infect."},{"key":"ref_42","unstructured":"MSD (2024, November 05). Merck\u2019s Nine-Valent Human Papillomavirus Vaccine, Gardaxius \u00ae9, Was Approved by China\u2019s National Medical Products Administration. Available online: https:\/\/www.msdchina.com.cn\/2024\/01\/09\/company_news_2024-01-09\/."},{"key":"ref_43","unstructured":"World Health Organization (2024, November 05). WHO Adds a Single-Dose Human Papillomavirus Vaccine. Available online: https:\/\/www.who.int\/zh\/news\/item\/04-10-2024-who-adds-an-hpv-vaccine-for-single-dose-use."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1038\/s41591-023-02658-0","article-title":"Durability of Single-dose HPV vaccination in young Kenyan women: Randomized controlled trial 3-year Results","volume":"29","author":"Barnabas","year":"2023","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1016\/S2214-109X(23)00586-7","article-title":"Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): An immunobridging analysis of randomised controlled Trials","volume":"12","author":"Baisley","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.amepre.2024.03.008","article-title":"Cost-Effectiveness of Human Papillomavirus Vaccination in the UK: Two Versus Single-Dose of Nonavalent HPV Vaccination","volume":"67","author":"Song","year":"2024","journal-title":"Am. J. Prev. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e654","DOI":"10.1016\/S1473-3099(24)00227-5","article-title":"Evaluation of a Single-dose HPV vaccine strategy for promoting vaccine, health, and gender Equity","volume":"24","author":"Mercuri","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_48","unstructured":"World Health Organization(WHO) (2024, September 05). List of Prequalified Vaccines. Available online: https:\/\/extranet.who.int\/prequal\/vaccines\/list-prequalified-vaccines."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Li, M., Zhao, C., Zhao, Y., Li, J., and Wei, L. (2023). Immunogenicity, efficacy, and safety of human papillomavirus vaccine: Data from China. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1112750"},{"key":"ref_50","first-page":"2927","article-title":"Research progress of human papillomavirus and its vaccine","volume":"54","author":"Dai","year":"2009","journal-title":"Sci. Bull."},{"key":"ref_51","first-page":"297","article-title":"Research status and vaccination policy of human papillomavirus vaccine","volume":"36","author":"Tian","year":"2024","journal-title":"Prev. Med. Shanghai"},{"key":"ref_52","first-page":"189","article-title":"Chinese expert consensus on clinical application of human papillomavirus vaccine","volume":"12","author":"Li","year":"2021","journal-title":"Chin. Med. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e1335","DOI":"10.1016\/S2214-109X(20)30277-1","article-title":"Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: A cost-effectiveness Analysis","volume":"8","author":"Zou","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_54","first-page":"769","article-title":"Research status and prospect of human papillomavirus vaccine","volume":"35","author":"Gao","year":"2022","journal-title":"Chin. J. Biolicals"},{"key":"ref_55","unstructured":"Path (2024, October 06). New HPV Vaccine from Zerun Bio Receives WHO Prequalification. Available online: https:\/\/www.path.org\/our-impact\/media-center\/new-hpv-vaccine-from-zerun-bio-receives-who-prequalification\/."},{"key":"ref_56","unstructured":"National Health Commission of China (2024, November 05). The HPV Vaccination Policy Has Covered About 40% of Girls of Appropriate Age in the Country. Available online: https:\/\/news.cctv.com\/2024\/10\/18\/ARTI0e4PDwAmsI5N0QODnETC241018.shtml."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10238-024-01470-5","article-title":"Viral vector-based therapeutic HPV vaccines","volume":"24","author":"Ji","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11523-020-00788-w","article-title":"Vaccine therapies for cancer: Then and Now","volume":"16","author":"Morse","year":"2021","journal-title":"Target. Oncol."},{"key":"ref_59","first-page":"376","article-title":"Expert consensus on therapeutic HPV vaccine research and development strategies","volume":"25","author":"Zhao","year":"2024","journal-title":"CJCOG"},{"key":"ref_60","first-page":"361","article-title":"Clinical research status of therapeutic HPV DNA vaccine","volume":"25","author":"Li","year":"2024","journal-title":"CJCOG"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"112981","DOI":"10.1016\/j.ejca.2023.112981","article-title":"Phase Ib\/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive Cancers","volume":"191","author":"Borcoman","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/IGC.0000000000001235","article-title":"A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer","volume":"28","author":"Basu","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_63","unstructured":"National Library of Medicine (2024, October 06). Information on Clinical Studies, Available online: https:\/\/clinicaltrials.gov\/search?limit=100."},{"key":"ref_64","first-page":"2586","article-title":"Application and safety of prophylactic human papillomavirus vaccines","volume":"40","author":"Luo","year":"2024","journal-title":"Chin. J. Clin. Pharmacol."},{"key":"ref_65","unstructured":"Drug Clinical Trial Registration and Information Disclosure Platform (2024, September 05). HPV Vaccine Enquiry. Available online: http:\/\/www.chinadrugtrials.org.cn\/clinicaltrials.searchlist.dhtml."},{"key":"ref_66","unstructured":"Center for Drug Evaluation, National Medical Products Administration (2024, September 05). Information of Accepted Varieties. Available online: https:\/\/www.cde.org.cn\/main\/xxgk\/listpage\/9f9c74c73e0f8f56a8bfbc646055026d."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1080\/21645515.2020.1823778","article-title":"Durability of response to VGX-3100 treatment of HPV16\/18 positive cervical HSIL","volume":"17","author":"Bhuyan","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-19-1513","article-title":"A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3","volume":"26","author":"Choi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: A worldwide incidence Analysis","volume":"8","author":"Georges","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"864","DOI":"10.20892\/j.issn.2095-3941.2020.0370","article-title":"Biological and clinical aspects of HPV-related cancers","volume":"17","author":"Szymonowicz","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell Carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Ebrahimi, N., Yousefi, Z., Khosravi, G., Malayeri, F.E., Golabi, M., Askarzadeh, M., Shams, M.H., Ghezelbash, B., and Eskandari, N. (2023). Human papillomavirus vaccination in low- and middle-income countries: Progression, barriers, and future prospective. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1150238"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1002\/ijc.31231","article-title":"Vaccination protects against invasive HPV-associated cancers","volume":"142","author":"Luostarinen","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_74","first-page":"1635","article-title":"A review of the impact and effectiveness of the quadrivalent human papillomavirus vaccine: 10 years of clinical experience in Canada","volume":"40","author":"Steben","year":"2018","journal-title":"JOGC"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1016\/j.vaccine.2018.08.009","article-title":"Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up","volume":"37","author":"Wei","year":"2019","journal-title":"Vaccine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ygyno.2019.03.253","article-title":"Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: Comparison with historic placebo Population","volume":"154","author":"Giuliano","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_78","first-page":"618","article-title":"Interpretation of NCCN Clinical practice Guidelines for Vaginal Cancer (2025, 1st edition)","volume":"40","author":"Jin","year":"2024","journal-title":"J. Pr. Obs. Gynaecol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.soncn.2019.03.002","article-title":"Scope and epidemiology of gynecologic cancers: An overview","volume":"35","author":"Ledford","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.ygyno.2020.05.683","article-title":"Time trends in the incidence and survival of vaginal squamous cell carcinoma and high-grade vaginal intraepithelial neoplasia in Denmark\u2014A nationwide population-based study","volume":"158","author":"Bertoli","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.amepre.2021.06.026","article-title":"High-grade vulvar, vaginal, and anal precancers among U.S. adolescents and young adults after human papillomavirus vaccine introduction","volume":"62","author":"Mix","year":"2022","journal-title":"Am. J. Prev. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jnci\/djaa209","article-title":"Real-world effectiveness of human papillomavirus vaccination against vulvovaginal high-grade precancerous lesions and cancers","volume":"113","author":"Dehlendorff","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_83","unstructured":"Committee of Gynecological Oncology, Chinese anti-Cancer Association (2021). Guidelines for the diagnosis and treatment of vulvar cancer (2021 edition). Chin. J. Cancer, 31, 533\u2013545."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Bechini, A., Moscadelli, A., Velpini, B., Bonito, B., Orlando, P., Putignano, P., Posi, S., Stacchini, L., Bonanni, P., and Boccalini, S. (2023). Efficacy of HPV vaccination regarding vulvar and vaginal recurrences in previously treated women: The need for further evidence. Vaccines, 11.","DOI":"10.3390\/vaccines11061084"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1080\/14760584.2019.1692658","article-title":"Prophylactic vaccination against human papillomaviruses to prevent vulval and vaginal cancer and their precursors","volume":"18","author":"Xu","year":"2019","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","article-title":"Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: A systematic review and meta-analysis","volume":"18","author":"Lin","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.32581","article-title":"Electrocautery ablation of anal high-grade squamous intraepithelial lesions: Effectiveness and key factors associated with outcomes","volume":"126","author":"Gaisa","year":"2020","journal-title":"Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e531","DOI":"10.1016\/S2352-3018(21)00108-9","article-title":"Epidemiology of anal human papillomavirus infection and High-grade squamous intraepithelial lesions in 29\u2009900 men according to HIV status, sexuality, and age: A collaborative pooled analysis of 64 Studies","volume":"8","author":"Wei","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ijc.34734","article-title":"Anal cancer screening results from 18-to-34-year-old men who have sex with men living with HIV","volume":"154","author":"Liu","year":"2024","journal-title":"Int. J. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/infdis\/jiad485","article-title":"High Risk of New HPV Infection Acquisition Among Unvaccinated Young Men","volume":"229","author":"Giuliano","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1473-3099(21)00327-3","article-title":"Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: Results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 Trial","volume":"22","author":"Goldstone","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/infdis\/jiaa306","article-title":"Vaccine effectiveness against prevalent anal and oral human papillomavirus infection among men who have sex with men-United States, 2016-2018","volume":"222","author":"Meites","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"de Ara\u00fajo, L.A., De Paula, A.A., de Paula, H.D., Ramos, J.E., de Oliveira, B.R., De Carvalho, K.P., Guimar\u00e3es, R.A., de Alencar, R.D., Duarte, E.C., and Rabelo Santos, S.H. (2018). Human papillomavirus (HPV) genotype distribution in penile carcinoma: Association with clinic pathological factors. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0199557"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Scurtu, L.G., Scurtu, F., Dumitrescu, S.C., and Simionescu, O. (2024). Squamous Cell Carcinoma In Situ-The Importance of Early Diagnosis in Bowen Disease, Vulvar Intraepithelial Neoplasia, Penile Intraepithelial Neoplasia, and Erythroplasia of Queyrat. Diagnostics, 14.","DOI":"10.3390\/diagnostics14161799"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Bai, J., Dong, X., Ning, T., Zhu, J., Wu, Z., Li, H., and Yu, M. (2024). Analysis of Multi-site HPV infection and vaccination willingness among men who have sex with men in Tianjin, China. Front. Public Health, 12.","DOI":"10.3389\/fpubh.2024.1453024"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/infdis\/jiab390","article-title":"Effectiveness of human papillomavirus (HPV) vaccination against penile hpv infection in men who have sex with men and transgender women","volume":"225","author":"Winer","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/jop.13513","article-title":"Epigenetics in the diagnosis and prognosis of head and neck cancer: A systematic review","volume":"53","author":"Lim","year":"2024","journal-title":"J. Oral. Pathol. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e702","DOI":"10.1002\/mco2.702","article-title":"Head and neck cancer: Pathogenesis and targeted therapy","volume":"5","author":"Liu","year":"2024","journal-title":"MedComm"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.semradonc.2017.08.008","article-title":"Head and neck cancer survivorship: Learning the needs, meeting the needs","volume":"28","author":"Ringash","year":"2018","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","article-title":"Head and neck Cancer","volume":"398","author":"Mody","year":"2021","journal-title":"Lancet"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.2017.75.0141","article-title":"Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States","volume":"36","author":"Chaturvedi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e1914031","DOI":"10.1001\/jamanetworkopen.2019.14031","article-title":"Risk of oral human papillomavirus infection among sexually active female adolescents receiving the quadrivalent vaccine","volume":"2","author":"Schlecht","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.pvr.2019.03.001","article-title":"Effect of vaccination against oral HPV-16 infection in high school students in the city of Cali, Colombia","volume":"7","author":"Castillo","year":"2019","journal-title":"Papillomavirus Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jama.2019.10508","article-title":"Prevalence of oral HPV infection in unvaccinated men and women in the United States, 2009\u20132016","volume":"322","author":"Chaturvedi","year":"2019","journal-title":"JAMA"},{"key":"ref_105","first-page":"100143","article-title":"Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study","volume":"8","author":"Damgacioglu","year":"2022","journal-title":"Lancet Reg. Health Am."},{"key":"ref_106","unstructured":"World Health Organization (2024, September 05). Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240014107."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Tobaiqy, M., and MacLure, K. (2024). A systematic review of human papillomavirus vaccination challenges and strategies to enhance uptake. Vaccines, 12.","DOI":"10.3390\/vaccines12070746"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1016\/j.vaccine.2017.05.025","article-title":"Prevalence of oral human papillomavirus by vaccination status among young adults (18\u201330 years old)","volume":"35","author":"Hirth","year":"2017","journal-title":"Vaccine"},{"key":"ref_109","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"102685","DOI":"10.1016\/j.amjoto.2020.102685","article-title":"HPV vaccination practices and attitudes among primary care physicians since FDA approval to age 45","volume":"41","author":"Petrusek","year":"2020","journal-title":"Am. J. Otolaryngol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3390\/curroncol28010097","article-title":"Evolution of public health human papillomavirus immunization programs in Canada","volume":"28","author":"Goyette","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"f924","DOI":"10.1136\/bmj.f924","article-title":"Australia launches national scheme to vaccinate boys against HPV","volume":"346","author":"Brill","year":"2013","journal-title":"BMJ"},{"key":"ref_113","first-page":"1072","article-title":"HPV vaccine should be promoted in adolescent men who have sex with men","volume":"35","author":"Zhou","year":"2014","journal-title":"Chin. J. Epidemiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e077341","DOI":"10.1136\/bmj-2023-077341","article-title":"Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: Population based observational study","volume":"385","author":"Falcaro","year":"2024","journal-title":"BMJ"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1071\/SH10020","article-title":"Cancers attributable to human papillomavirus Infection","volume":"7","author":"Grulich","year":"2010","journal-title":"Sex. Health"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1086\/425906","article-title":"Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: The EXPLORE study","volume":"190","author":"Vittinghoff","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1080\/21645515.2019.1625644","article-title":"A ten-year study of immunogenicity and safety of the AS04-HPV-16\/18 vaccine in adolescent girls aged 10-14 years","volume":"15","author":"Schwarz","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Herrero, R., Quint, W., Hildesheim, A., Gonzalez, P., Struijk, L., Katki, H.A., Porras, C., Schiffman, M., Rodriguez, A.C., and Solomon, D. (2013). Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0068329"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"FUTURE II, Study Group (2007). Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med., 356, 1915\u20131927.","DOI":"10.1056\/NEJMoa061741"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Rashid, H., Dey, A., Wang, H., and Beard, F. (2024). Sustained Decline in Hospitalisations for Anogenital Warts in Australia: Analysis of National Hospital Morbidity Data 2003-2020. Trop Med Infect Dis, 9.","DOI":"10.3390\/tropicalmed9040079"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Hull, B., Hendry, A., Dey, A., Brotherton, J., Macartney, K., and Beard, F. (2023). Annual immunisation coverage report 2021. Commun Dis Intell, 47.","DOI":"10.33321\/cdi.2023.47.47"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S1473-3099(21)00071-2","article-title":"Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus Gender-neutral vaccination programme: An analysis of national sentinel surveillance data from 2004\u201318","volume":"21","author":"Chow","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"126215","DOI":"10.1016\/j.vaccine.2024.126215","article-title":"How has Post-implementation surveillance of high-coverage vaccination with HPV16\/18-AS04 vaccine in England added to evidence about its cross-protective Effects?","volume":"42","author":"Anderson","year":"2024","journal-title":"Vaccine"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.vaccine.2024.01.094","article-title":"Costs of human papillomavirus vaccine delivery in Low- and middle-income countries: A systematic Review","volume":"42","author":"Slavkovsky","year":"2024","journal-title":"Vaccine"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Soi, C., Babigumira, J.B., Chilundo, B., Muchanga, V., Matsinhe, L., Gimbel, S., Augusto, O., and Sherr, K. (2019). Implementation strategy and cost of Mozambique\u2019s HPV vaccine demonstration Project. BMC Public Health, 19.","DOI":"10.1186\/s12889-019-7793-y"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1073\/pnas.1515528113","article-title":"National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States","volume":"113","author":"Durham","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.3802\/jgo.2024.35.e85","article-title":"Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low\/middle-income country Setting","volume":"35","author":"Termrungruanglert","year":"2024","journal-title":"J. Gynecol. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/21645515.2018.1514227","article-title":"Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine","volume":"15","author":"Guevara","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"100401","DOI":"10.1016\/j.eclinm.2020.100401","article-title":"Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries","volume":"23","author":"Kjaer","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s10067-017-3782-7","article-title":"Erratum to: Serious adverse events after HPV vaccination: A critical review of randomized trials and post-marketing case series","volume":"36","year":"2017","journal-title":"Clin. Rheumato"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"f5906","DOI":"10.1136\/bmj.f5906","article-title":"Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: Cohort Study","volume":"347","author":"Pasternak","year":"2013","journal-title":"BMJ"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/bcp.13841","article-title":"Safety profile of human papilloma virus vaccines: An analysis of the US vaccine adverse event reporting system from 2007 to 2017","volume":"85","author":"Bonaldo","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.1016\/j.vaccine.2020.06.039","article-title":"Adverse events following HPV vaccination: 11 years of surveillance in Australia","volume":"38","author":"Phillips","year":"2020","journal-title":"Vaccine"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jama.2014.16946","article-title":"Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system","volume":"313","author":"Scheller","year":"2015","journal-title":"JAMA"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.adaj.2019.10.010","article-title":"Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines: Umbrella review of systematic reviews","volume":"151","author":"Villa","year":"2020","journal-title":"J. Am. Dent. Assoc."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"l1161","DOI":"10.1136\/bmj.l1161","article-title":"Prevalence of Cervical Disease at Age 20 after Immunisation with Bivalent HPV Vaccine at Age 12-13 in Scotland: Retrospective Population Study","volume":"365","author":"Palmer","year":"2019","journal-title":"BMJ"},{"key":"ref_137","first-page":"201","article-title":"Scottish Screening: No Cases of Invasive Cervical Cancer in Women Who Received at Least One Dose of Bivalent HPV Vaccine at 12 or 13 Years of Age","volume":"110","author":"Barry","year":"2024","journal-title":"Am. Fam. Physician"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2412391","DOI":"10.1080\/21645515.2024.2412391","article-title":"The 13-year long-term follow-up on the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in Chinese females vaccinated at 20\u201345 years of Age","volume":"20","author":"Wen","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"van Eer, K., Dzebisasjvili, T., Steenbergen, R.D.M., and King, A.J. (2024). Comparative Analysis of HPV16 Variants in the Untranslated Regulatory Region, L1, and E6 Genes among Vaccinated and Unvaccinated Young Women: Assessing Vaccine Efficacy and Viral Diversity. Viruses, 16.","DOI":"10.3390\/v16091381"},{"key":"ref_140","first-page":"415","article-title":"Initial Evidence of a Possible Effect of HPV Vaccination on Cancer Incidence in Germany\u2014Focus on Cervical Cancer","volume":"121","author":"Grieger","year":"2024","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e070115","DOI":"10.1136\/bmj-2022-070115","article-title":"Human papillomavirus vaccination and cervical cancer risk","volume":"379","author":"Rahangdale","year":"2022","journal-title":"BMJ"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/11\/1291\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:35:01Z","timestamp":1760114101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/11\/1291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":141,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["vaccines12111291"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12111291","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]}}}